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Introduction
The exercise-induced stress response is an adaptational 
homeostatic shift intended to facilitate the demands put on 
the body by physical exertion. Most stressors, including heat, 
pain, trauma and exercise, stimulate prostaglandin synthesis. 
The mechanisms underlying this stimulation usually involve 
the release of  pro-inflammatory cytokines with subsequent 
induction of  prostaglandin synthesis which influences the 
central neuroendocrine regulatory mechanisms.14 This stres-
sor-induced prostaglandin synthesis, in turn, initiates and 
modulates many aspects of  the stress response such as 
neuroendocrine, autonomic nervous system, metabolic and 
temperature changes. The pathways through which prostag-
landins are involved in the cortisol stress response include 
a direct influence on the release of  corticotropin-releasing 
hormone (CRH) and/or antidiuretic hormone (ADH) from the 
paraventricular nucleus (PVN), and indirect stimulation of  the 
PVN via the central noradrenergic neurons.8,14 Prostaglan-
dins are further involved in the exercise-induced autonomic 
nervous system response7 and in the increase in body tem-
perature and other metabolic adaptations.14 Several other 
aspects of  the exercise-related neuroendocrine response, 
which are under control of  the hypothalamus and the hypoth-
alamo-pituitary axis, are also influenced by prostaglandins 
and other eicosanoids.8 It therefore speaks for itself  that any 
medication that interferes with eicosanoid metabolism could 
have the potential to influence the exercise-induced stress 
response. 
Eicosanoids are produced throughout the body under 
the influence of  the cyclooxygenase (COX) activities 
of  prostaglandin endoperoxide H synthases (PGHSs). 
Two PGHS isozymes exist, PGHS-1 and PGHS-2, 
commonly referred to as cyclooxygenase-1 or COX-1 
and cyclooxygenase-2 or COX-2.  COX-1 is thought to be 
constitutively expressed in virtually all tissues and to be 
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objective. This study investigated the effects of  single dos-
ages of  the non-steroidal anti-inflammatory drug (NSAID) 
naproxen, and of  the coxib, rofecoxib, on the exercise-in-
duced stress response.
Design. Eight subjects (age 20.9 ± 1.1 years, weight 70.4 
± 3.9 kg, height 170.9 ± 6.7 cm, body surface area 1.82 ± 
0.09 m2, body mass index 24.1 ± 1.3 kg.m-2) took part in a 
double-blind, drug-placebo, cross-over design study. The 
experimental procedures were performed on 3 occasions 
on each volunteer, i.e. once on placebo, once on naproxen 
(single dose of  1 000 mg) and once on rofecoxib (single 
dose of  50 mg).
results. Mean post-exercise cortisol values were signifi-
cantly higher than pre-exercise values with the subjects on 
placebo (p = 0.0365) and rofecoxib (p = 0.0208), but not 
on naproxen (p = 0.0732). Post-exercise oral temperatures 
were significantly higher than pre-exercise temperature 
values on placebo (p = 0.0153) and rofecoxib (p = 0.0424), 
but not on naproxen (p = 0.5444).
conclusion. The results of  this study suggest a role for 
cyclooxygenase-1 (COX-1) in the exercise-induced cortisol 
and temperature response to exercise.
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involved in normal physiological functions such as protecting 
the kidney and the gastric mucosa and maintaining vascular 
homeostasis.14,18 COX-2, although initially thought not to 
exist constitutively, is now, in humans, known to be found as 
such in several types of  tissues.10 The expression of  COX-2 
can further be induced in all tissues tested thus far, and its 
expression is stimulated in a rapid, exaggerated fashion by 
mitogens, growth factors and pro-inflammatory cytokines.10,18 
It is at present assumed that COX-2, which is situated in the 
cerebral blood vessels and thus easily accessed by blood-
borne cytokines for the induction of  prostaglandins, could 
be responsible for many of  the physical stress-induced 
adaptations.14 
COX inhibitors have an influence on eicosanoid metabolism 
and many of  the effects of  non-steroidal anti-inflammatory 
drugs (NSAIDs) are exerted through interference with this 
effect.20 COX inhibitors block the biosynthesis of  prostanoids 
by inhibiting the COX activities of  PGHSs. Their most generally 
known pharmacological effects are their anti-inflammatory, 
analgesic, antipyretic and platelet-inhibiting actions, but 
they are also said to be of  value in the prevention of  colon 
cancer (COX-2), as well as in slowing down the progression 
of  Alzheimer’s disease,18 and there are indications that 
they may be of  benefit during exercise by decreasing post-
exercise muscle soreness and decline in strength.1
Although these drugs are known for their anti-inflammatory 
and analgesic effects there are health risks, such as an 
increase in gastrointestinal permeability, associated with the 
indiscriminate use of  anti-inflammatory drugs.12 A number of  
other negative side-effects have been reported for NSAIDs, 
including potential ulcerogenic and nephrotoxic effects and 
there are indications that they may inhibit protein synthesis 
in skeletal muscle after eccentric resistant exercise,21 
augment the exercise-induced increase in gastrointestinal 
permeability12 and decrease muscle blood flow during 
exercise.5 
The considered-safer COX-2 selective inhibitors such 
as rofecoxib and celecoxib have been associated with 
ulcer-related side-effects and increases in cardiovascular 
morbidity.13
NSAIDs may theoretically also influence the adaptive 
exercise-induced stress response through suppression of  
the synthesis of  those prostaglandins that stimulate the 
fever response, the sympathetic nervous system and the 
hypothalamo-pituitary-adrenocortical axis.7,8,18 
The frequent use of  COX inhibitors by athletes is a well-
known occurrence. In view of  their role in the development 
of  the exercise-induced stress response, COX inhibitors 
could theoretically also be expected to have an effect on 
the performance of  athletes. Despite evidence that aspirin 
(acetylsalicylic acid) can modulate the secretion of  many 
hormones, there is as yet not conclusive evidence that any of  
the COX inhibitors has a marked effect on the neuroendocrine 
and metabolic homeostatic shift of  exercise,8,16 and more 
research is needed.
Three broad classes of  COX inhibitors are generally 
known.9 The best known is aspirin, synthesised from salicylic 
acid, which inhibits the activity of  COX-1 by irreversibly 
acetylating a serine residue at position 529. The second 
class is the NSAIDs such as indomethacin and naproxen that 
inhibit both forms of  the enzyme, i.e. COX-1 and COX-2. The 
third class is the selective COX-2 inhibitors, i.e. the coxibs 
such as rofecoxib. This study investigated the effects of  the 
non-selective COX inhibitor naproxen (Naprosyn) and the 
selective COX-2 inhibitor rofecoxib (Vioxx) on the treadmill-
induced stress response and on the recovery period.
Naproxen reduces the synthesis of  prostaglandins by 
inhibiting COX activities of  both isoforms of  PGHSs, i.e. 
COX-1 and COX-2. The plasma half-life of  naproxen is 12 
- 15 hours and peak plasma concentrations are seen in about 
2 hours.7,20 Rofecoxib is 50 times more selective in inhibiting 
the COX-2 isoenzyme. The plasma half-life is 10 - 17 hours 
and peak plasma concentrations are seen in 2 - 3 hours.9 
Although referred to as a COX-2 inhibitor, an alternative term 
to COX-2 inhibitor would be ‘COX-1 sparing’.
The aim of  this study was to investigate the effects of  
single dosages of  the NSAID, naproxen (1 000 mg), and the 
coxib, rofecoxib (50 mg), on the expression of  the treadmill-
induced stress response as reflected in free salivary cortisol 
levels, heart rate, oral temperature and other metabolic 
parameters.
Methods
subjects and experimental design
The effects of  the 2 NSAIDs on the exercise-induced stress 
response were investigated in healthy students in a double-
blind, drug-placebo, cross-over design study in which each 
subject served as his/her own control. All tests started at the 
same time of  the day and experimental conditions were simi-
lar for all exposures. 
The mean age of  the students (N = 8) was 20.9 ± 1.1 
years, weight 70.4 ± 3.9 kg, height 170.9 ± 6.7 cm, body 
surface area 1.82 ± 0.09 m2 and body mass index 24.1 ± 1.3 
kg.m-2. During the first week of  the study students had general 
medical examinations and those with either hypertension (> 
140/90 mmHg), hypotension (< 100/60 mmHg), or any other 
pathological condition or risk factor, as well as students on 
chronic medication or performance-enhancing drugs were 
excluded. Students who developed any health complication 
such as colds or flu during the study were excluded. Other 
than the treadmill procedures of  the study no strenuous 
physical activity was allowed over the 4 weeks each subject 
was involved in the study and subjects had to refrain from 
alcohol intake on the days before the experiments.  During 
the same week the maximal oxygen consumption (VO2max) 
of  each student was determined, the procedures of  the 
study explained and informed consent forms signed. 
Ethical clearance (Research Ethics Committee, Faculty of  
Health Sciences, University of  Pretoria, clearance number: 
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173/2002) was obtained for the study and all participants 
gave written informed consent.
testing and procedures
The experimental procedure was performed on 3 separate 
occasions by each participant, i.e. once on placebo, once on 
naproxen (single dose of  1 000 mg) and once on rofecoxib 
(single dose of  50 mg) swallowed 2 hours before initiation of  
the treadmill procedure. The drug or placebo was adminis-
tered randomly by a third party in a cross-over design study 
performed double blind. A washout period of  7 days passed 
between the experimental days. Testing started at the same 
time of  day in consideration of  circadian rhythmicity. 
The VO2max tests comprised incremental increases in 
running speed at a constant gradient of  2°. The following 
protocol was used: 3 minutes at 8 km.h-1 and 2 minutes at 
10, 12, 14, 16 and 17 km.h-1 respectively on a motorised 
treadmill with the subjects clothed in jogging shoes and light 
clothing. Expiratory oxygen, carbon dioxide and heart rates 
were continuously measured every 10 seconds during the 
tests (Schiller Cardiovit, CS100, Baar, Switzerland).
The study proper started the second week. On arrival for 
the experiment (07h00) the heart rate monitor was fitted, oral 
temperature was taken sublingually for 3 minutes using a 
clinical thermometer and thereafter a salivary sample was 
collected for cortisol determination. This is referred to as time 
PRE1. Thereafter the drug or placebo was administered and a 
standardised breakfast consisting of  toast and fruit juice was 
consumed. Two hours after administration of  the drug/placebo 
the oral   temperature was again taken and saliva collected for 
cortisol analysis (PRE2). The treadmill procedure consisting 
of  3 exercise intensities equivalent to 50%, 60% and 75% 
of  maximal oxygen expenditure for 10, 15, and 5 minutes, 
respectively, was started immediately. Heart rate recordings 
were obtained continuously throughout the procedure. 
Salivary samples were again collected at the end of  the 
exercise protocol (POST1), and at 30 minutes (POST2), 60 
minutes (POST3) and 120 minutes (POST4) post-exercise. 
The collected salivary samples were centrifuged at 1 000 g 
for 10 minutes at 4ºC and aliquots of  the supernatants were 
transferred to Eppendorf  tubes and stored at –20ºC until 
analysis by enzyme-linked immunosorbent assay (ELISA) 
(DRG GmbH, Marburg, Germany). Oral temperatures were 
recorded at the same times salivary samples were taken.
statistics
Data were analysed using the appropriate analysis of  vari-
ance (ANOVA) for a three-period cross-over experimental de-
sign, with factors for treatment period, treatment, carry-over 
and subjects. The analyses were also done by adjusting for 
baseline values, i.e. baseline values were used as covariates. 
The covariates were not significant for any of  the variables. 
Within treatments, the exercise-induced effect was assessed 
using the paired t-test after establishing that there was no 
carry-over effect between treatments. As the sample was 
relatively small the conclusions for the latter were confirmed 
using Wilcoxin’s matched pairs signed-rank test. Differences 
were considered statistically significant when p < 0.05.19
results
Table I (A-C) shows the means, standard deviations and p-
values (one-way ANOVA) for cortisol, heart rate and oral tem-
perature directly before the drug/placebo was administered 
(PRE1), 2 hours after drug/placebo administration, i.e. direct-
ly before initiation of  the treadmill procedure (PRE2), imme-
diately after completion of  the treadmill procedure (POST1), 
30 minutes after the treadmill procedure (POST2), 60 min-
utes after the treadmill procedure (POST3), and 2 hours after 
the treadmill procedure (POST4). No significant differences 
were seen between the values obtained on placebo and with 
either of  the 2 NSAIDs, or between the values on naproxen 
and on rofecoxib. Table I (D) shows the peak values obtained 
during exercise for the metabolic parameters. No significant 
differences were found between the values obtained on the 
drugs and placebo or between those on the 2 drugs.
The exercise-induced response and the post-exercise 
recovery for the various parameters are recorded in Table I. 
It can be seen that the treadmill procedure served its function 
as physical stressor as typical stress responses were 
observed over the exercise period in all 3 groups. The mean 
post-exercise cortisol values (POST1) were significantly 
higher than the pre-exercise (PRE2) cortisol values with the 
subjects on placebo (p = 0.0365) and rofecoxib (p = 0.0208), 
but not on naproxen (p = 0.0732). There were, however, 
no significant differences between the exercise-induced 
increases in cortisol secretion (POST1 minus PRE2) with 
subjects on placebo, naproxen and rofecoxib (p = 0.9055). 
The mean post-exercise heart rate (POST1) was significantly 
higher than the pre-exercise (PRE2) heart rate values with 
subjects on placebo (p = 0.0001), naproxen (p = 0.0001) and 
rofecoxib (p = 0.0001). No significant differences were found 
between the exercise-induced increases in heart rate in the 3 
groups (p = 0.3841). The post-exercise temperature (POST1) 
was significantly higher than the pre-exercise (PRE2) 
temperature values on placebo (p = 0.0153) and rofecoxib 
(p = 0.0424), but not on naproxen (p = 0.5444). Once again 
no statistically significant differences were found between 
the exercise-induced responses on the 3 substances (p = 
0.6701).
The mean post-exercise METS (1 MET = 3.5 ml O2.kg
-1. 
min-1; POST1) was significantly higher than the pre-exercise 
(PRE2) METS values on placebo (p = 0.0001), naproxen 
(p = 0.0001) and rofecoxib (p = 0.0001). The means of  the 
oxygen expenditure at 75% VO2max (VO2/min and VO2/kg/min) 
were significantly higher than the pre-exercise expenditure 
on placebo (p = 0.0001 and p = 0.0001), naproxen (p = 
0.0001 and p = 0.0001) and rofecoxib (p = 0.0001 and p = 
0.0001). No statistical differences were, however, found in 
the increases (∆) over the exercise period for METS, VO2ml/
min or VO2ml/min/kg between subjects on placebo, naproxen or 
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rofecoxib (p = 0.5122; p = 0.4764; p = 0.4433).
No statistically valid differences were found over the 
recovery period between the results obtained on the 2 drugs 
or between the drugs and the placebo.
Discussion
In this study good stress responses were observed over the 
treadmill procedure for all parameters tested, indicating that 
the exercise regimen was correct. There were no significant 
differences between the absolute values over time for any of  
the stress parameters irrespective of  whether the subjects 
were on placebo, naproxen or rofecoxib. Significant increas-
es were found for all stress parameters over the exercise pe-
riod (POST1 v. PRE2) when subjects were on placebo and 
on rofecoxib, respectively. However, the pre-post increases in 
cortisol concentrations and oral temperatures were not sta-
tistically significant with subjects on naproxen. Naproxen, as 
previously mentioned, belongs to the second class of  anti-
inflammatory drugs that inhibit both forms of  the enzyme, i.e. 
COX-1 and COX-2. Rofecoxib, on the other hand, belongs to 
the third class, i.e. the selective COX-2 inhibitors. The fact 
that the non-selective COX inhibitor, naproxen, but not the 
selective COX-2 inhibitor, rofecoxib, had an inhibiting effect 
on the cortisol and temperature response is an indication 
that the suppressive effects may be mediated by suppress-
ing COX-1 activity.
The results of  this study are unexpected as one would 
have thought that rofecoxib rather than naproxen would have 
had the suppressive effect. In theory, the slightly longer time 
to peak plasma concentration (Cmax) for rofecoxib than for 
naproxen might have been a confounding factor, which would 
have meant that the exercise could have been performed 
before peak plasma values were reached. This should, 
however, have been reflected in the recovery period. This 
taBle I. Between-treatment comparisons for mean cortisol, heart rate, oral temperature and Mets over the experi-
mental period. exercise-induced values represent the change in the respective values of the variables from either 
Pre2 to Post1 (cortisol and oral temperature) or Pre2 to 7% of Vo2max during exercise (heart rate and Mets). 
(Pre1 = t0 min, Pre2 = t120 min, Post1 = t10 min, Post2 = t180 min, Post3 = t210 min, and Post = t270 min.)
     Variable  Placebo (± sD)  naproxen (± sD)  rofecoxib (± sD)
     PRE 1   7.6 ± 3.7   7.8 ± 6.4   7.4 ± 3.6
A.      PRE 2  1.8 ± 1.5   1.4 ± 1.3   1.1 ± 0.6
Mean cortisol concentration (ng/ml) POST 1  3.8 ± 2.8   3.0 ± 1.7   3.8 ± 2.4
     POST 2  2.7 ± 1.7   3.2 ± 1.3   3.6 ± 2.4
     POST 3  1.4 ± 1.0   2.0 ± 0.7   2.1 ± 1.2
     POST 4  0.8 ± 0.5   1.7 ± 1.2   1.6 ± 1.3
     PRE  87.8 ± 8.6   83.6 ± 5.6   83.7 ± 10.1
B.      50%  113.8 ± 8.9  112.6 ± 12.1  111.1 ± 7.5
Mean heart rate (beats/min)  60%  148.1 ± 21.2  148.2 ± 19.6  156.2 ± 15.5
     75%  162.8 ± 13.3  169.8 ± 13.1  159.8 ± 24.2
     POST  120.2 ± 18.0  122.9 ± 25.2  114.5 ± 11.8
     PRE 1  36.5 ± 0.2   36.4 ± 0.3   36.2 ± 0.3 
C.     PRE 2  36.5 ± 0.2   36.5 ± 0.4   36.2 ± 0.3
Mean oral temperature (ºC)  POST 1  36.7 ± 0.3   36.6 ± 0.3   36.6 ± 0.3
     POST 2  36.9 ± 0.1   36.6 ± 0.4   36.8 ± 0.2
     POST 3  36.7 ± 0.3   36.6 ± 0.2   36.7 ± 0.2
     POST 4  36.6 ± 0.3   36.6 ± 0.2   36.5 ± 0.3
     Rest  1.1 ± 0.6   1.1 ± 0.5   0.9 ± 0.8
D.     50%  4.6 ± 0.9   5.1 ± 0.9   5.1 ± 1.0
METS    60%  6.9 ± 1.2   7.4 ± 1.5   7.6 ± 1.4
     75%  7.8 ± 0.8   8.6 ± 0.9   8.0 ± 1.6
     ∆ MET  6.6 ± 0.7   7.5 ± 1.0   7.1 ± 1.3
     ∆ VO2/min  1.6 ± 0.2   1.9 ± 0.3   1.7 ± 0.3
Exercise-induced response  ∆ VO2/kg/min 23.2 ± 2.5   26.4 ± 3.4   24.8 ± 4.4
     ∆ Cortisol  1.9 ± 2.1   1.6 ± 2.1   2.7 ± 2.5
     ∆ Heart rate 75.0 ± 15.0  86.2 ± 14.9  72.2 ± 28.4
     ∆ Oral temp 0.2 ± 0.2   0.1 ± 0.4   0.4 ± 0.4
SD = standard deviation; METS = 3.5 ml O2.kg
-1.min-1
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was not the case as there were no statistical differences for 
any parameter between placebo, naproxen and rofecoxib 
over  the post-exercise recovery period.
It is of  interest that the lower cortisol response seen in this 
study with subjects on naproxen, compared with subjects on 
placebo, was also reported previously with aspirin.8  Further 
support for our findings, i.e. that COX-1 is involved in the 
exercise-induced stress response, is derived from indications 
that the COX-1 gene might be important in temperature 
regulation and the pyresis that occurs in the absence 
of  infections, as opposed to COX-2 gene involvement in 
infection- and lipopolysaccharide-induced pyresis.4
Subsequent to completion of  this study rofecoxib was 
voluntarily withdrawn worldwide on 30 September 2004 by 
Merck and Co.  This followed the confirmation of  previous 
results that the selective COX-2 inhibitor rofecoxib increases 
the relative risk for cardiovascular events such as heart 
attack and stroke.3,6
Stress induces upregulation of  COX-2 in endothelial cells 
and since COX-2 selective inhibitors such as rofecoxib have 
no antiplatelet activities (COX-1) the imbalance between 
prothrombotic eicosanoids (TXA2) and vasodilatory and anti-
aggregatory PGI2 forms the theoretical basis for the reported 
adverse clinical outcome.2,17
Other COX-2 inhibitors such as celecoxib are still marketed 
for acute and chronic inflammatory pain. The association 
between celecoxib and adverse cardiovascular outcomes 
seems to be less pronounced.11 The reason for this is not 
clear but may be due to different pharmacokinetics compared 
with rofecoxib. Valdecoxib has also been associated with an 
increase in reinfarction rates in patients receiving the drug 
after a myocardial infarction.15  The potential for adverse 
cardiovascular events therefore seems to be related to the 
mechanism of  action of  COX-2 inhibitors.
The frequent use of  NSAIDs by athletes before, during 
and after competitions raises the question whether it may 
have an influence on the exercise-induced stress response. 
This, and other investigations indicate that anti-inflammatory 
drugs may have an effect on the exercise-induced stress 
response and that the performance and perhaps even health 
of  the athletes may be negatively affected by the use of  
these drugs. The results of  this study therefore indicate that 
more care needs to be taken with the selection of  NSAIDs if  
athletes have to use them during training and competitions. 
Coaches and physical conditioning specialists also need to 
be informed about the different physiological mechanisms 
that are influenced by NSAID drugs. This will enable them to 
give athletes proper advice with regard to the use of  NSAIDs. 
It may further also help coaches and physical conditioning 
specialists to understand the development of  certain 
unexpected exercise-induced stress responses if  the athlete 
uses a specific NSAID.
conclusion
Although the results of  this study point towards a role for 
COX-1 in the exercise-induced cortisol and temperature re-
sponse, more studies of  this nature, as well as studies involv-
ing NSAIDs and endurance exercise, are urgently required to 
come to a better understanding of  the exact role of  COXs in 
the exercise-induced response and therefore of  the potential 
effects of  NSAIDs.
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